Vivera Pharmaceuticals

Name

Vivera Pharmaceuticals

Legal name

Vivera Pharmaceuticals, Inc.

Website

https://viverapharmaceuticals.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals and Medical Devices

NAICS

Pharmaceutical Preparation Manufacturing (325412), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Pharmaceutical Preparations (2834), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)

akta.pro secondary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

Keywords

• Drug delivery systems
• Medical device manufacturing
• Pharmaceutical products
• Diagnostic testing services
• Telemedicine solutions

Headquarters

HQ city

Newport Beach

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Products: Revenue from proprietary pharmaceutical products utilizing the TABMELT sublingual drug delivery technology, including neuroscience medications for psychiatric and fluency disorders.
2. Medical Devices: Revenue from ZICOH dose-controlled medication dispensing devices and other medical devices under development.
3. COVID-19 Testing Services: Revenue from providing COVID-19 testing solutions including RT-PCR, antigen, and antibody testing through concierge laboratory services.
4. TABMELT Licensing: Global exclusivity to license the patented and patent-pending TABMELT sublingual drug delivery system for pharmaceutical use of therapeutic compounds.
5. Personal Protective Equipment (PPE): Revenue from manufacturing and distribution of PPE including gloves and masks made in the USA for first responders and healthcare centers.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Vivera Pharmaceuticals develops and commercializes proprietary pharmaceutical products using the patented TABMELT sublingual drug delivery system and manufactures patented medical devices including the ZICOH dose-controlled electronic prescription dispensing device and the MDZone portable telemedicine station. The company also provides COVID-19 diagnostic testing services and PPE, and licenses TABMELT technology globally to pharmaceutical manufacturers for use with therapeutic compounds.

Product overview

Vivera Pharmaceuticals is an innovative, science-driven biopharma and medtech company organized into multiple divisions (Technologies, Biosciences, Medical Devices, Advanced Diagnostics, Neurosciences, Medical Technologies) offering a portfolio of patented products and drug delivery systems. The core product portfolio centers on TABMELT (sublingual drug delivery technology), ZICOH (dose-controlled electronic prescription dispensing device), MDZone (portable telemedicine station), and Lab Port (diagnostic testing software). Vivera is vertically integrated with patented technology, manufacturing capabilities, and distribution for its products, with a focus on addressing the opioid crisis through non-addictive pain management solutions and prescription drug abuse deterrence.

Differentiator

Problem solved

Functional benefit

Brands

• ZICOH: Intelligent, dose-controlled electronic prescription dispensing device designed to improve medication safety, compliance, and adherence. Part of a closed-loop medication management system.
• MDZone
• TABMELT
• Vivera Cares
• Lab Port

Products and services

• TABMELT Sublingual Drug Delivery System A patented and patent-pending sublingual drug delivery system that allows patients to dissolve tablets under the tongue, bypassing the GI tract and first-pass liver metabolism for more instantaneous and accurate absorption than oral drug delivery. Licensed globally to pharmaceutical manufacturers for use with therapeutic compounds.
• ZICOH Dose-Controlled Medication Delivery Device An intelligent, dose-controlled electronic prescription dispensing device with fingerprint authentication, real-time monitoring of patient usage and compliance, and a closed-loop medication management system that connects the prescription supply chain from manufacturers to patients. Designed to deter prescription drug abuse and address the opioid crisis.
• MDZone Portable Telemedicine Station A portable, HIPAA-compliant telemedicine station that allows patients to access healthcare professionals remotely. Customizable with features including facial recognition, temperature monitoring, and sanitization capabilities.
• Lab Port Diagnostic Testing Software An innovative software system designed to streamline the diagnostic testing process for patients and providers, featuring a user-friendly interface for capturing patient data prior to administering medical tests.
• Speech Fluency Evaluation and Feedback Device A U.S. patent-allowed device for continuous monitoring of a patient's speech to provide accurate assessment and feedback for patients who stutter. Collects condition information allowing clinicians to monitor therapeutic effects and adjust treatment plans.
• COVID-19 Concierge Testing and Vaccination Services Concierge COVID-19 testing and vaccine clinic services including RT-PCR, antigen, and antibody testing, delivered on-site to enterprise clients including healthcare providers, government, educational institutions, long-term care facilities, event venues, and businesses.
• Personal Protective Equipment (PPE) Manufactured gloves and masks made in the USA, distributed to first responders and healthcare centers for pandemic response.

Quantifiable outcome

• Reduced risk of addiction and overdose through dose-controlled medication delivery and prescription compliance monitoring
• +1 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Eight partnerships are on record, tiered minor and core.

• Mazars USA LLPminorOthers · 9 July 2021International audit firm engaged by Vivera to complete public audit for fiscal years 2019 and 2020, supporting the company's financial transparency and reporting requirements.
• Areum Bio LLCcoreChannel Partner/ Reseller/ Distributor · 30 June 2021Channel partnership with Areum Bio LLC, a diagnostic testing distributor, to expand the national distribution of Access Bio's CareStart COVID-19 Rapid Antigen Tests. Vivera leverages its extensive network of healthcare providers and organizations for distribution.
• Burkhan GroupcoreStrategic or Co-development Partner · 25 January 2021Partnership between Vivera Pharmaceuticals and Burkhan Group for COVID-19 testing initiative in Southern California. Together the two companies are expanding access to rapid testing as area businesses develop back-to-work protocols, focusing on the film, television, hospitality, and travel sectors.
• Access Bio, Inc.coreChannel Partner/ Reseller/ DistributorAccess Bio, Inc. is a New Jersey-based diagnostic manufacturer focused on research, development, and production of diagnostics for infectious diseases. Partnered with Vivera and Areum Bio for CareStart COVID-19 Rapid Antigen Test distribution.
• Managed Health Care Associates, Inc. (MHA)coreStrategic or Co-development PartnerMHA is the largest alternate site Group Purchasing Organization (GPO) in the country, encompassing Atlantic Health Partners (nation's largest vaccine buying group). Vivera sponsors MHA's Annual Business Summit and showcases Advanced Diagnostics offerings and products from Pharmaceutical and Medical Device divisions.
• Central City Community Health CenterminorStrategic or Co-development PartnerPartnered with Central City Community Health Center (federally qualified non-profit health care center) for COVID-19 and vaccination clinics throughout Los Angeles and Orange County regions, serving medically underserved and low-income populations.
• Capitol Health ServicesminorStrategic or Co-development PartnerPartnership with Capitol Health Services, the health services provider for California State capitol staff and lawmakers, to host dedicated vaccine clinics. Working with Sacramento County Public Health and EquiVax for monthly vaccine and testing events.
• University of California at Riverside (UCR)minorStrategic or Co-development PartnerVivera is developing its relationship with UCR to evaluate the potential to develop and license additional targeted novel therapeutics for the Neurosciences Division. Working with Dr. Gerald A. Maguire on neuroscience research initiatives.

Scale indicators3 records

Recent moves12 records

Expansion highlights6 records

Direct peers

• Aquestive Therapeutics: Aquestive Therapeutics specializes in sublingual and oral film drug delivery technologies, including treatments for CNS conditions. It is directly comparable to Vivera's TABMELT sublingual drug delivery system, competing in the same product category and therapeutic areas.
• IntelGenx Technologies: IntelGenx develops oral thin film and sublingual drug delivery platforms for pharmaceutical partners. It is a direct competitor to Vivera's TABMELT sublingual technology, addressing similar bioavailability and patient adherence use cases.
• BioDelivery Sciences International: BDSI developed abuse-deterrent opioid formulations and pain management products using proprietary drug delivery technology. Its overlap with Vivera's ZICOH abuse-deterrent platform and focus on non-addictive pain management makes it a direct peer.
• Collegium Pharmaceutical: Collegium Pharmaceutical focuses on responsible pain management with abuse-deterrent, extended-release opioid products. It competes directly with Vivera's ZICOH device and opioid deterrence thesis.
• Orexo: Orexo is a Swedish specialty pharmaceutical company developing improved sublingual and mucosal drug delivery formulations, particularly for opioid use disorder. It is directly comparable to Vivera's TABMELT platform and CNS focus.

Broad incumbents

• Teva Pharmaceutical Industries: Teva is a major global pharmaceutical company headquartered in Israel (where Vivera recently secured TABMELT patent protection) and has been identified as a potential TABMELT licensing partner. As a broad incumbent with overlapping generic and specialty pharma operations, it represents both a competitor and a key commercialization channel for Vivera's technology.
• Pfizer: Pfizer is a major global pharmaceutical manufacturer with extensive CNS, pain management, and drug delivery capabilities. As a broad incumbent with the scale to license or compete with TABMELT technology, it represents a relevant peer for partnership or competitive dynamics.
• Becton Dickinson (BD): BD is a global medical device and drug delivery leader with substantial pharmaceutical systems, injection, and dispensing device portfolios. It competes broadly with Vivera's ZICOH dose-controlled medication dispensing platform and other medical device offerings.

Emerging players

• Pear Therapeutics: Pear Therapeutics developed prescription digital therapeutics for CNS conditions including substance use disorder, overlapping with Vivera's MDZone telemedicine and ZICOH prescription management approach to behavioral and addiction treatment.
• Nemaura Medical: Nemaura Medical develops needle-free drug delivery and continuous diagnostic monitoring technologies. Its combination of drug delivery and connected diagnostics overlaps with Vivera's ZICOH dose-controlled delivery and Lab Port diagnostic software strategy.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCuwhFJi4Or0HWt6EpuVuqQw
• Facebookfacebook.com/viverapharma
• LinkedInlinkedin.com/company/viverapharmaceuticals
• Instagraminstagram.com/viverapharma
• Xx.com/viverapharma

Revenue estimate

Valuation estimate

Number of profiles

Profiles19 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Vivera Pharmaceuticals